Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
BRCA-ассоциированный рак яичников (опыт отделения химиотерапии ФГБУ «РОНЦ им. Н.Н.Блохина» Минздрава России)
BRCA-ассоциированный рак яичников (опыт отделения химиотерапии ФГБУ «РОНЦ им. Н.Н.Блохина» Минздрава России)
Хохлова С.В., Горбунова В.А., Любченко Л.Н., Имянитов Е.Н. BRCA-ассоциированный рак яичников (опыт отделения химиотерапии ФГБУ «РОНЦ им. Н.Н.Блохина» Минздрава России). Современная Онкология. 2016; 18 (1): 37–44.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
В последние годы основные научные направления при раке яичников связаны с попыткой индивидуализации лечения на основании молекулярно-биологических прогностических и предиктивных маркеров. В 10–15% случаев в возникновении рака яичников участвуют нарушения в генах BRCA1 и BRCA2. Главной функцией комплекса белков BRCA является регуляция восстановления двунитевых разрывов ДНК по механизму гомологичной рекомбинации. Результатом дисфункции BRCA может быть нарушение BRCA-ассоциированного механизма репарации ДНК. Как следствие, эти опухоли могут быть чрезвычайно чувствительны к ДНК-повреждающим цитостатикам – производным платины. Несколько исследований докладывает о лучшей выживаемости пациенток с наличием мутаций в генах BRCA, по сравнению со спорадическим раком яичников. Данные об особенностях течения и лечения больных раком яичников с наличием мутаций в генах BRCA1, 2 в российской популяции больных крайне скудны.
Ключевые слова: мутации BRCA1, 2, рак яичников, препараты платины.
Key words: BRCA1, 2 mutations, ovarian cancer, platinum-based drugs.
Ключевые слова: мутации BRCA1, 2, рак яичников, препараты платины.
________________________________________________
Key words: BRCA1, 2 mutations, ovarian cancer, platinum-based drugs.
Полный текст
Список литературы
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2012 г. Вестн. Российского онкологического научного центра им. Н.Н.Блохина РАМН. 2013; 22 (3): 9–142. / Davydov M.I., Aksel' E.M. Statistika zlokachestvennykh novoobrazovanii v Rossii i stranakh SNG v 2012 g. Vestn. Rossiiskogo onkologicheskogo nauchnogo tsentra im. N.N.Blokhina RAMN. 2013; 22 (3): 9–142. [in Russian]
2. Имянитов Е.Н. Общие представления о наследственных опухолевых синдромах. Практическая онкология. 2014; 15 (3): 101. / Imianitov E.N. Obshchie predstavleniia o nasledstvennykh opukholevykh sindromakh. Prakticheskaia onkologiia. 2014; 15 (3): 101. [in Russian]
3. Максимов С.Я., Имянитов Е.Н. и др. Клинические особенности BRCA-позитивного рака яичников. Сиб. онкологический журн. 2013; 6 (60). / Maksimov S.Ia., Imianitov E.N. i dr. Klinicheskie osobennosti BRCA-pozitivnogo raka iaichnikov. Sib. onkologicheskii zhurn. 2013; 6 (60). [in Russian]
4. Мамедов В.А., Бахидзе Е.В., Имянитов Е.Н. Оценка эффективности лекарственного лечения у больных раком яичников с различным статусом гена BRCA. Сиб. онкологический журн. 2009; S1: 129–30. / Mamedov V.A., Bakhidze E.V., Imianitov E.N. Otsenka effektivnosti lekarstvennogo lecheniia u bol'nykh rakom iaichnikov s razlichnym statusom gena BRCA. Sib. onkologicheskii zhurn. 2009; S1: 129–30. [in Russian]
5. Смирнова Т.Ю., Поспехова Н.И., Любченко Л.Н. и др. Высокая частота мутаций в генах BRCA1 и BRCA2 при раке. Бюлл. эксперимент. биологии и медицины. 2007; 144 (7): 93–5. / Smirnova .Iu., Pospekhova N.I., Liubchenko L.N. i dr. Vysokaia chastota mutatsii v genakh BRCA1 i BRCA2 pri rake. Biull. eksperiment. biologii i meditsiny. 2007; 144 (7): 93–5. [in Russian]
6. Fedorova OE, Liubchenko LN, Paiadini IuG et al. Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and priary multiple tumors involving the ovaries. Patients of Russian population using biochips. Mol Biol (Mosk) 2007; 41: 37.
7. Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013; 11 (1): 2. doi: 10.1186/1897-4287-11-2.
8. Imyanitov EN. Ovarian cancer genome. Methods Mol Biol 2013; 1049: 3–7.
9. Imyanitov EN, Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011; 9 (1): 5. doi: 10.1186/1897-4287-9-5.
10. Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New En J Med 2006; 354 (1): 34–43.
11. Bolton K, Chenevix-Trench G et al. Association between BRCA1 and BRCA2 Mutations and Survival in women with Invasive Epithelial Ovarian Cancer. JAMA 2012; 307 (4): 382–90.
12. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283 (17): 2260–5.
13. Cass I, Baldwin R et al. Improved Survival in women with BRCA-associated Ovarian carcinoma. Am Cancer Soc 2003; 97 (9).
14. Chan JK, Tian C, Monk BJ et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112 (10: 2202–10.
15. Deng CX, Brodie SG. Role of BRCA 1 and its interacting proteins. Bioessays 2010; 22 (8): 728–37.
16. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917–21.
17. Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; c. 928562.
18. Lesnock JL et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer 2013; 108 (6): 1231–7.
19. Leunen K et al. Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? Intl J Gynecologic Cancer 2009; 19 (9): 1501–4.
20. Parvin JD. BRCA 1 at a branch point. Proc Natl Acad Dci USA 2001; 98 (11): 5952–4.
21. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335 (19): 1413–6.
22. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecologic Cancer 2014; 24 (3): 488–95.
23. Yang D. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
24. Yang D, Khan S, Sun Y et al. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
25. Zhong Q, Peng H et al. Effects of BRCA1-and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. Clin Cancer Res 2014; 21 (1): 211–20.
26. Ashworth A et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785–90.
27. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66: 8109–15.
28. Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–51.
29. Ledermann J, Harter P. Olaparib maintenance therapy in patients with platinum- sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancel. Published Online May 30, 2014 http://dx.doi.org/10.1016/ S1470-2045(14)70228-1
2. Imianitov E.N. Obshchie predstavleniia o nasledstvennykh opukholevykh sindromakh. Prakticheskaia onkologiia. 2014; 15 (3): 101. [in Russian]
3. Maksimov S.Ia., Imianitov E.N. i dr. Klinicheskie osobennosti BRCA-pozitivnogo raka iaichnikov. Sib. onkologicheskii zhurn. 2013; 6 (60). [in Russian]
4. Mamedov V.A., Bakhidze E.V., Imianitov E.N. Otsenka effektivnosti lekarstvennogo lecheniia u bol'nykh rakom iaichnikov s razlichnym statusom gena BRCA. Sib. onkologicheskii zhurn. 2009; S1: 129–30. [in Russian]
5. Smirnova .Iu., Pospekhova N.I., Liubchenko L.N. i dr. Vysokaia chastota mutatsii v genakh BRCA1 i BRCA2 pri rake. Biull. eksperiment. biologii i meditsiny. 2007; 144 (7): 93–5. [in Russian]
6. Fedorova OE, Liubchenko LN, Paiadini IuG et al. Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and priary multiple tumors involving the ovaries. Patients of Russian population using biochips. Mol Biol (Mosk) 2007; 41: 37.
7. Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013; 11 (1): 2. doi: 10.1186/1897-4287-11-2.
8. Imyanitov EN. Ovarian cancer genome. Methods Mol Biol 2013; 1049: 3–7.
9. Imyanitov EN, Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011; 9 (1): 5. doi: 10.1186/1897-4287-9-5.
10. Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New En J Med 2006; 354 (1): 34–43.
11. Bolton K, Chenevix-Trench G et al. Association between BRCA1 and BRCA2 Mutations and Survival in women with Invasive Epithelial Ovarian Cancer. JAMA 2012; 307 (4): 382–90.
12. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283 (17): 2260–5.
13. Cass I, Baldwin R et al. Improved Survival in women with BRCA-associated Ovarian carcinoma. Am Cancer Soc 2003; 97 (9).
14. Chan JK, Tian C, Monk BJ et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112 (10: 2202–10.
15. Deng CX, Brodie SG. Role of BRCA 1 and its interacting proteins. Bioessays 2010; 22 (8): 728–37.
16. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917–21.
17. Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; c. 928562.
18. Lesnock JL et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer 2013; 108 (6): 1231–7.
19. Leunen K et al. Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? Intl J Gynecologic Cancer 2009; 19 (9): 1501–4.
20. Parvin JD. BRCA 1 at a branch point. Proc Natl Acad Dci USA 2001; 98 (11): 5952–4.
21. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335 (19): 1413–6.
22. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecologic Cancer 2014; 24 (3): 488–95.
23. Yang D. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
24. Yang D, Khan S, Sun Y et al. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
25. Zhong Q, Peng H et al. Effects of BRCA1-and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. Clin Cancer Res 2014; 21 (1): 211–20.
26. Ashworth A et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785–90.
27. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66: 8109–15.
28. Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–51.
29. Ledermann J, Harter P. Olaparib maintenance therapy in patients with platinum- sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancel. Published Online May 30, 2014 http://dx.doi.org/10.1016/ S1470-2045(14)70228-1
2. Имянитов Е.Н. Общие представления о наследственных опухолевых синдромах. Практическая онкология. 2014; 15 (3): 101. / Imianitov E.N. Obshchie predstavleniia o nasledstvennykh opukholevykh sindromakh. Prakticheskaia onkologiia. 2014; 15 (3): 101. [in Russian]
3. Максимов С.Я., Имянитов Е.Н. и др. Клинические особенности BRCA-позитивного рака яичников. Сиб. онкологический журн. 2013; 6 (60). / Maksimov S.Ia., Imianitov E.N. i dr. Klinicheskie osobennosti BRCA-pozitivnogo raka iaichnikov. Sib. onkologicheskii zhurn. 2013; 6 (60). [in Russian]
4. Мамедов В.А., Бахидзе Е.В., Имянитов Е.Н. Оценка эффективности лекарственного лечения у больных раком яичников с различным статусом гена BRCA. Сиб. онкологический журн. 2009; S1: 129–30. / Mamedov V.A., Bakhidze E.V., Imianitov E.N. Otsenka effektivnosti lekarstvennogo lecheniia u bol'nykh rakom iaichnikov s razlichnym statusom gena BRCA. Sib. onkologicheskii zhurn. 2009; S1: 129–30. [in Russian]
5. Смирнова Т.Ю., Поспехова Н.И., Любченко Л.Н. и др. Высокая частота мутаций в генах BRCA1 и BRCA2 при раке. Бюлл. эксперимент. биологии и медицины. 2007; 144 (7): 93–5. / Smirnova .Iu., Pospekhova N.I., Liubchenko L.N. i dr. Vysokaia chastota mutatsii v genakh BRCA1 i BRCA2 pri rake. Biull. eksperiment. biologii i meditsiny. 2007; 144 (7): 93–5. [in Russian]
6. Fedorova OE, Liubchenko LN, Paiadini IuG et al. Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and priary multiple tumors involving the ovaries. Patients of Russian population using biochips. Mol Biol (Mosk) 2007; 41: 37.
7. Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013; 11 (1): 2. doi: 10.1186/1897-4287-11-2.
8. Imyanitov EN. Ovarian cancer genome. Methods Mol Biol 2013; 1049: 3–7.
9. Imyanitov EN, Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011; 9 (1): 5. doi: 10.1186/1897-4287-9-5.
10. Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New En J Med 2006; 354 (1): 34–43.
11. Bolton K, Chenevix-Trench G et al. Association between BRCA1 and BRCA2 Mutations and Survival in women with Invasive Epithelial Ovarian Cancer. JAMA 2012; 307 (4): 382–90.
12. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283 (17): 2260–5.
13. Cass I, Baldwin R et al. Improved Survival in women with BRCA-associated Ovarian carcinoma. Am Cancer Soc 2003; 97 (9).
14. Chan JK, Tian C, Monk BJ et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112 (10: 2202–10.
15. Deng CX, Brodie SG. Role of BRCA 1 and its interacting proteins. Bioessays 2010; 22 (8): 728–37.
16. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917–21.
17. Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; c. 928562.
18. Lesnock JL et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer 2013; 108 (6): 1231–7.
19. Leunen K et al. Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? Intl J Gynecologic Cancer 2009; 19 (9): 1501–4.
20. Parvin JD. BRCA 1 at a branch point. Proc Natl Acad Dci USA 2001; 98 (11): 5952–4.
21. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335 (19): 1413–6.
22. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecologic Cancer 2014; 24 (3): 488–95.
23. Yang D. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
24. Yang D, Khan S, Sun Y et al. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
25. Zhong Q, Peng H et al. Effects of BRCA1-and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. Clin Cancer Res 2014; 21 (1): 211–20.
26. Ashworth A et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785–90.
27. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66: 8109–15.
28. Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–51.
29. Ledermann J, Harter P. Olaparib maintenance therapy in patients with platinum- sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancel. Published Online May 30, 2014 http://dx.doi.org/10.1016/ S1470-2045(14)70228-1
________________________________________________
2. Imianitov E.N. Obshchie predstavleniia o nasledstvennykh opukholevykh sindromakh. Prakticheskaia onkologiia. 2014; 15 (3): 101. [in Russian]
3. Maksimov S.Ia., Imianitov E.N. i dr. Klinicheskie osobennosti BRCA-pozitivnogo raka iaichnikov. Sib. onkologicheskii zhurn. 2013; 6 (60). [in Russian]
4. Mamedov V.A., Bakhidze E.V., Imianitov E.N. Otsenka effektivnosti lekarstvennogo lecheniia u bol'nykh rakom iaichnikov s razlichnym statusom gena BRCA. Sib. onkologicheskii zhurn. 2009; S1: 129–30. [in Russian]
5. Smirnova .Iu., Pospekhova N.I., Liubchenko L.N. i dr. Vysokaia chastota mutatsii v genakh BRCA1 i BRCA2 pri rake. Biull. eksperiment. biologii i meditsiny. 2007; 144 (7): 93–5. [in Russian]
6. Fedorova OE, Liubchenko LN, Paiadini IuG et al. Analysis of BRCA1/2 and CHEK2 mutations in ovarian cancer and priary multiple tumors involving the ovaries. Patients of Russian population using biochips. Mol Biol (Mosk) 2007; 41: 37.
7. Imyanitov EN, Byrski T. Systemic treatment for hereditary cancers: a 2012 update. Hered Cancer Clin Pract 2013; 11 (1): 2. doi: 10.1186/1897-4287-11-2.
8. Imyanitov EN. Ovarian cancer genome. Methods Mol Biol 2013; 1049: 3–7.
9. Imyanitov EN, Moiseyenko V.M. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011; 9 (1): 5. doi: 10.1186/1897-4287-9-5.
10. Armstrong DK et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. New En J Med 2006; 354 (1): 34–43.
11. Bolton K, Chenevix-Trench G et al. Association between BRCA1 and BRCA2 Mutations and Survival in women with Invasive Epithelial Ovarian Cancer. JAMA 2012; 307 (4): 382–90.
12. Boyd J, Sonoda Y, Federici MG et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA 2000; 283 (17): 2260–5.
13. Cass I, Baldwin R et al. Improved Survival in women with BRCA-associated Ovarian carcinoma. Am Cancer Soc 2003; 97 (9).
14. Chan JK, Tian C, Monk BJ et al. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study. Cancer 2008; 112 (10: 2202–10.
15. Deng CX, Brodie SG. Role of BRCA 1 and its interacting proteins. Bioessays 2010; 22 (8): 728–37.
16. Farmer H, McCabe N, Lord CJ et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434 (7035): 917–21.
17. Karami F, Mehdipour P. A comprehensive focus on global spectrum of BRCA1 and BRCA2 mutations in breast cancer. Biomed Res Int 2013; c. 928562.
18. Lesnock JL et al. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer 2013; 108 (6): 1231–7.
19. Leunen K et al. Does paclitaxel-carboplatin chemotherapy in a dose-dense regimen enhance survival of BRCA-related ovarian cancer patients? Intl J Gynecologic Cancer 2009; 19 (9): 1501–4.
20. Parvin JD. BRCA 1 at a branch point. Proc Natl Acad Dci USA 2001; 98 (11): 5952–4.
21. Rubin SC, Benjamin I, Behbakht K et al. Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. N Engl J Med 1996; 335 (19): 1413–6.
22. Safra T, Rogowski O, Muggia FM. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer. Int J Gynecologic Cancer 2014; 24 (3): 488–95.
23. Yang D. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
24. Yang D, Khan S, Sun Y et al. Association between BRCA2 but not BRCA1 mutations and beneficial Survival, Chemotherapy sensitivy, and gene Mutator Phenotype in Patients with ovarian cancer. JAMA 2011; 306 (14): 1557–65.
25. Zhong Q, Peng H et al. Effects of BRCA1-and BRCA2-related Mutations on Ovarian and Breast Cancer Survival: A Meta-analysis. Clin Cancer Res 2014; 21 (1): 211–20.
26. Ashworth A et al. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008; 26: 3785–90.
27. McCabe N, Turner NC, Lord CJ et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to Poly(ADP-Ribose) polymerase inhibition. Cancer Res 2006; 66: 8109–15.
28. Audeh MW et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial. Lancet 2010; 376: 245–51.
29. Ledermann J, Harter P. Olaparib maintenance therapy in patients with platinum- sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial. Lancel. Published Online May 30, 2014 http://dx.doi.org/10.1016/ S1470-2045(14)70228-1
Авторы
С.В.Хохлова*1, В.А.Горбунова1, Л.Н.Любченко1, Е.Н.Имянитов2
1 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
2 ФГБУ Научно-исследовательский институт онкологии им. Н.Н.Петрова Минздрава России. 197758, Россия, Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68
*SVKhokhlova@mail.ru
1 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
2 N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation. 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68
*SVKhokhlova@mail.ru
1 ФГБУ Российский онкологический научный центр им. Н.Н.Блохина Минздрава России. 115478, Россия, Москва, Каширское ш., д. 23;
2 ФГБУ Научно-исследовательский институт онкологии им. Н.Н.Петрова Минздрава России. 197758, Россия, Санкт-Петербург, пос. Песочный, ул. Ленинградская, д. 68
*SVKhokhlova@mail.ru
________________________________________________
1 N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of the Russian Federation. 115478, Russian Federation, Moscow, Kashirskoe sh., d. 23;
2 N.N.Petrov Research Institute of Oncology of the Ministry of Health of the Russian Federation. 197758, Russian Federation, Saint Petersburg, pos. Pesochnyi, ul. Leningradskaia, d. 68
*SVKhokhlova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.